vaccine's safety and effectiveness are expected no sooner than in 16 months, Borobia said the transition to Phase 3 clinical trials was permissible upon satisfactory preliminary results.The epidemiological situation in Spain, which used to be Europe's second-worst outbreak at the beginning of the year, worsened again in July.